The aim of this article is to investigate the relation of the anti-inflammatory effect of pioglitazone with cardiac autonomic function and metabolic control in diabetic patients. In this prospective open label trial, 36 type 2 diabetic patients (age 60 +/- 10, 20 M) without overt cardiovascular disease were randomized to add pioglitazone (30 mg) to their therapy or to continue standard therapy. C-reactive protein (CRP) serum levels, metabolic parameters and cardiac autonomic function (assessed by heart rate variability [HRV] on 24-h ECG Holter monitoring) were measured at baseline and after 3 months. Clinical and laboratory variables were similar in the two groups. No significant changes were observed after 3 months for metabolic and anthropometric parameters, except for a mild increase in HDL levels in the pioglitazone group only (P = 0.04 vs. controls). CRP levels decreased significantly at follow-up in the pioglitazone group (3.2 +/- 1.97 vs. 2.37 +/- 1.56 mg/l) but not in the control group (3.0 +/- 1.92 vs. 3.93 +/- 2.14 mg/l; P = 0.003). No differences were found in basal and follow-up HRV variables between the two groups. In type 2 diabetic patients pioglitazone exerts favourable effects on inflammation even after short-term therapy. This effect precedes those on metabolic and anthropometric parameters and is not associated with changes in cardiac autonomic function.

Nerla, R., Pitocco, D., Zaccardi, F., Scalone, G., Coviello, I., Mollo, R., Ghirlanda, G., Lanza, G. A., Crea, F., Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes, <<ACTA DIABETOLOGICA>>, 2010; (Dicembre): 117-122. [doi:10.1007/s00592-009-0150-3] [http://hdl.handle.net/10807/11013]

Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes

Nerla, Roberto;Pitocco, Dario;Zaccardi, Francesco;Scalone, Giancarla;Coviello, Ilaria;Mollo, Roberto;Ghirlanda, Giovanni;Lanza, Gaetano Antonio;Crea, Filippo
2010

Abstract

The aim of this article is to investigate the relation of the anti-inflammatory effect of pioglitazone with cardiac autonomic function and metabolic control in diabetic patients. In this prospective open label trial, 36 type 2 diabetic patients (age 60 +/- 10, 20 M) without overt cardiovascular disease were randomized to add pioglitazone (30 mg) to their therapy or to continue standard therapy. C-reactive protein (CRP) serum levels, metabolic parameters and cardiac autonomic function (assessed by heart rate variability [HRV] on 24-h ECG Holter monitoring) were measured at baseline and after 3 months. Clinical and laboratory variables were similar in the two groups. No significant changes were observed after 3 months for metabolic and anthropometric parameters, except for a mild increase in HDL levels in the pioglitazone group only (P = 0.04 vs. controls). CRP levels decreased significantly at follow-up in the pioglitazone group (3.2 +/- 1.97 vs. 2.37 +/- 1.56 mg/l) but not in the control group (3.0 +/- 1.92 vs. 3.93 +/- 2.14 mg/l; P = 0.003). No differences were found in basal and follow-up HRV variables between the two groups. In type 2 diabetic patients pioglitazone exerts favourable effects on inflammation even after short-term therapy. This effect precedes those on metabolic and anthropometric parameters and is not associated with changes in cardiac autonomic function.
Inglese
Nerla, R., Pitocco, D., Zaccardi, F., Scalone, G., Coviello, I., Mollo, R., Ghirlanda, G., Lanza, G. A., Crea, F., Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes, <<ACTA DIABETOLOGICA>>, 2010; (Dicembre): 117-122. [doi:10.1007/s00592-009-0150-3] [http://hdl.handle.net/10807/11013]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/11013
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact